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OBJECTIVES: Multiple myeloma (MM) is a malignancy of plasma cells that results         
in an overproduction of light and heavy chain monoclonal immunoglobulins. Multiple 
myeloma imposes a signiﬁcant economic and humanistic burden on patients and 
society. The present study is aimed to assess the burden of multiple myeloma in        
epidemiologic and economic terms. METHODS: A retrospective, naturalistic longi-   
tudinal study on the occurrence, outcomes and cost of multiple myeloma using an 
administrative database was performed. We selected residents of a North-eastern      
Region of Italy, who had the multiple myeloma ﬁrst hospital admission during the       
period 2001–2005, and we followed them up until December 31, 2006, death or 
transfers. Direct medical costs were quantiﬁed in the perspective of the Regional 
Health Service. RESULTS: out of a population if 1.2 million inhabitants, we enrolled 
517 patients (52% female) leading to a crude incidence of 8.6/100.000 person-years. 
During the period of observation, 364 (70.4%) subjects died. Total health care costs 
per patients over the maximum of follow-up were a78,020 for the subjects younger 
than 70 years old and a23,096 in older group. CONCLUSIONS: The overall cost of 
MM is substantial, particularly in the ﬁrst year after diagnosis and for hospital care. 
The natural history of the disease requires a great absorption of resources in the early 
phases after diagnosis and in the late stages of the disease. Multiple myeloma imposes   
a signiﬁcant epidemiologic and economic burden to the healthcare- system and 
society.
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A DESCRIPTIVE ANALYSIS OF THE ASSOCIATION BETWEEN BREAST 
CANCER RISK, BONE MINERAL DENSITY AND FRACTURES IN POST-
MENOPAUSAL WOMEN IN THE CANADIAN MULTICENTRE 
OSTEOPOROSIS STUDY
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OBJECTIVES: To explore potential correlations among risk factors for breast cancer, 
bone mineral density (BMD) and fractures in post-menopausal women (PMW). 
METHODS: A cohort of PMW aged 50–85 without breast cancer history (BC) was 
obtained from the Canadian Multicentre Osteoporosis Study (CaMos) database, a 
prospective and longitudinal cohort study following subjects for 10 years. Cross-tabu-
lations were calculated between baseline 5-year breast cancer risk score quartiles (Gail 
scores) and baseline family history of cancer (breast, ovarian, prostate), age group, 
incident breast cancer (during follow-up), fracture (any minimal trauma, or vertebral 
fracture based on x-ray), and BMD status (normal, osteopenia, osteoporosis). Another 
cross-tabulation was performed for baseline BMD by incident BC. RESULTS: Gail 
score quartiles for 4,770 PMW were: Q1  1.329; 1.329  Q2  1.581; 1.581  Q3 
 1.968; Q4  1.968; mean  1.77). Among 1,159 PMW with family history of cancer, 
76% had Gail scores in the 3rd (17%) and 4th (59%) quartiles. Older individuals had 
higher Gail scores, as proportions aged 50–59, 60–69, and 70 within Q3 and 
Q4 were 8.5% & 11.7%; 30.3% & 22.4%; and 43.3% & 29.4%, respectively. Nearly 
4% (n  184) had incident BC, and most cases were diagnosed in women with higher 
baseline Gail scores (33% in Q3; 30% in Q4). Almost 27% (1,263) had prevalent 
fracture and these women had higher Gail scores (35% in Q3: 27% in Q4). In PMW 
with baseline osteopenia, 30% were in Q3 and 22% in Q4, while for osteoporosis 
the proportions were 34% and 26%, respectively. Among PMW with incident BC, 
70% had baseline osteopenia (55%) or osteoporosis (15%). CONCLUSIONS: 
The association between risk of breast cancer and fractures in PMW is uncertain. 
Additional analyses adjusting for multiple confounders in this population are needed 
to help improve our understanding of this complex relationship.
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IMPLEMENTATION OF CLINICAL INTERVENTION REPORTING SYSTEM 
FOR PHARMACISTS
Kamal S
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OBJECTIVES: To evaluate pharmacy clinical interventions done in the children cancer 
hospital Egypt during the period from July 2007 to March 2009. METHODS: The 
clinical intervention reports were recorded into a database made by the department 
of pharmaceutical services. RESULTS: A total of 362 Pharmacy Clinical interventions 
were recorded(this number constitute only 40% of the daily interventions), 52(14.4%) 
were category A, which is Incomplete prescription (missing: Generic name, drug form, 
strength, dose, duration.....etc.); 58(16%) were category B, which is Irrational pre-
scribing; 39(10.8%) were category C, which is Excessive quantities, Unnecessary 
medication Duplication of therapy; 152 (41.99%) were category D, which is inap-
propriate dosage/route/ﬂow rate/duration of therapy, where from the 152 Intervention 
in category D 65% was Inappropriate dosage, 15% inappropriate ﬂow rate and 20% 
inappropriate duration of treatment; 25 (6.9%) were category E Drug-drug interac-
tions; 8(2.2%) were category F, which is Allergy to a prescribed medicine; 11(3%) 
were category G, which is Drug incompatibilities-Disease e.g. G6PDD-Food -Lab tests; 
14(3.9%) were category H, which is Drug monitoring is needed; 1 Intervention was 
category I, which is Dose adjustment is needed due to renal insufﬁciency and 2 were 
category J which is Dose adjustment is needed due to hepatic insufﬁciency. CONCLU-
SIONS: The 362 Pharmacy clinical interventions were all medical errors that were 
prevented by the pharmacy staff. The major intervention was mainly category D 
regarding inappropriate dosage. The Pharmacy Clinical Intervention database will be 
used now on the ﬂoors, to encourage participation from the pharmacists and increased 
the reporting.
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OBJECTIVES: To evaluate the impact, on Brazilian Public Health Care System (SUS) 
budget, of reimbursing for dasatinib for newly diagnosed CML patients who become 
imatinib-resistant. The budget impact analysis is conducted for three consecutive 
years. METHODS: Due to the rapid evolution of the disease, a monthly-cycle Markov 
model incorporating clinical and epidemiological data was developed to determine the 
target population throughout the analysis time. The base case analysis for imatinib-
resistant CML patients compared the costs of imatinib (600–800 mg/day), versus 
dasatinib (100–140 mg/day). Disease progression depended on the best treatment 
response rates taken from START clinical trials. Pharmaceutical costs were obtained 
according to the ofﬁcial price and standard government discounting procedures, but 
alternative costing scenarios were also evaluated. Data sources for the epidemiological 
and treatment regimen distributions input variables include reports from the Brazilian 
National Cancer Institute (INCA) and published literature. Probability sensitivity 
analysis (PSA) was conducted to account for uncertainties of the model. The three-year 
time period was considered adequate as approval of nilotinib in the near future will 
impact the market share structure for imatinib-resistant CML patients for later years. 
RESULTS: Annual incidence of CML was estimated as 1431. Within one year’s time, 
481 CML patients are expected to become imatinib-resistant. In the base case, the 
net budget impact was a savings of about a1,900,000 in 2009 to savings around 
a3,300,000 in 2011, with a total savings of approximately a8,000,000/three years 
time frame. The net impact on the alternative costing scenarios remained negative. 
The acceptability curve generated from the PSA showed a 100% probability of savings 
on the base case. CONCLUSIONS: The inclusion of dasatinib as 2nd line therapy for 
newly diagnosed CML patients who have become imatinib-resistant in Brazil would 
result in increasingly and signiﬁcant savings, even after accounting for uncertainties 
of the model.
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BUDGETARY IMPACT OF ORAL CHEMOTHERAPY: REAL-WORLD DATA 
ANALYSIS FROM PAYERS’ PERSPECTIVES IN BRAZIL
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OBJECTIVES: In Brazil, health insurance companies (HIC) must offer coverage for 
intravenous chemotherapy drugs (IVCD), but not for oral chemotherapy drugs (OCD). 
We aimed to evaluate the incremental costs and the budgetary impact of the incorpora-
tion of OCD, using real world data. METHODS: We prospectively collected data 
during 2008, on chemotherapy usage in 14 HIC, on a population of 2 million people 
from different regions in Brazil. First we calculated the costs of the IVCD actually 
used. After that, we indentiﬁed which patients would have formal indication for OCD 
either as a substitutive treatment or in association with IVCD. Then, we calculated 
the costs associated with this intervention. Later, the budgetary impact of using OCD 
for eligible patients was totaled. Only drug acquisition costs were taken into account. 
We were conservative and assumed a “worst case scenario” (WCS) approach as the 
base case, therefore skewing results against OCD. RESULTS: During the one-year 
period, 1328 patients that received intravenous chemotherapy also had formal indica-
tion to receive OCD. The cost of the treatment actually done was US$19,630,000. If 
OCD were also used, the incremental cost would be an additional US$5,500,000. The 
relative incremental cost associated with OCD is therefore US$2.75 per capita per 
year or US$0.23 per capita per month, in a WCS. CONCLUSIONS: The budgetary 
impact linked with the adoption of OCD is of US$0.23 per capita per month, in Brazil, 
according to this real world data analysis.
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OBJECTIVES: New health technologies and drugs have great impact on costs, mainly 
in cancer treatment. It was previously shown that EBM can be a powerful tool in 
preventing the coverage of experimental treatments. However, it is usual to receive 
appeals contesting the denied coverage. Our goal is to deﬁne the proﬁle of appeals in 
a large health care plan (HP) in Sao Paulo. METHODS: We collected all data on 
billing and contestation relative to chemotherapy treatments performed by this HP 
